Search for drugs:
Typing the drug name to query
OBINUTUZUMAB
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- CLINICAL PHARMACOLOGY
- Pharmacodynamics
- Cardiac Electrophysiology
- The potential effects of GAZYVA on the QTc interval have not been studied.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
5
24087
Other ADRs
9559
38372028
Odds Ratio = 0.834
Drug Property Information
ATC Code(s):
- L01XC15 - obinutuzumab
- L01XC1 -
- L01XC - Monoclonal antibodies
- L01X - OTHER ANTINEOPLASTIC AGENTS
- L01 - ANTINEOPLASTIC AGENTS
- L - ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Active Ingredient:OBINUTUZUMAB
Active Ingredient UNII:O43472U9X8
Drugbank ID:DB08935
PubChem Compound:N/ADIR Classification
CAS Number:
Dosage Form(s):injection, solution, concentrate
Route(s) Of Administrator:intravenous
Daily Dose:
Chemical Structure: 
SMILE Code:
Reference
N/A
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.